您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Eptifibatide
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Eptifibatide
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Eptifibatide图片
CAS NO:188627-80-7
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
依替巴肽是一种环状七肽,可作为活化血小板糖蛋白 IIb/IIIa 受体的竞争性拮抗剂,具有抗血小板活性。
Cas No.188627-80-7
别名依替巴肽
Canonical SMILESO=C([C@H](CC1=CNC2=C1C=CC=C2)N3)N4[C@](CCC4)([H])C(N[C@H](C(N)=O)CSSCCC(N[C@@H](CCCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C3=O)=O)=O)=O)=O
分子式C35H49N11O9S2
分子量832
溶解度DMF: 30 mg/ml,DMSO: 14 mg/ml,Ethanol: 5 mg/ml,PBS (pH 7.2): 5 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd= 120 nM) that inhibits platelet aggregation.1,2Eptifibatide prevents binding of the adhesion proteins fibrinogen and von Willebrand factor to GPIIb/IIIa on the surface of activated platelets to prevent aggregation and thrombus formation.3It inhibits ADP-induced citrated blood aggregation (IC50= 0.11-0.22 μg/ml)in vitroandin vivo(IC50= 52 μg/ml in porcine plasma).1,4Formulations containing eptifibatide have been used to reduce risk of thrombolysis in myocardial infarction in patients undergoing percutaneous coronary intervention.5

1.Harder, S., Klinkhardt, U., Graff, J., et al.In vitro dose response to different GPIIb/IIIa-antagonists: Inter-laboratory comparison of various platelet function testsThromb. Res.102(1)39-48(2001) 2.Moser, M., Bertram, U., Peter, K., et al.Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregatesJ. Cardiovasc. Pharmacol.41(4)586-592(2003) 3.Scarborough, R.M.Development of eptifibatideAm. Heart J.138(6 Pt 1)1093-1104(1999) 4.Ciborowski, M., and Tomasiak, M.The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood plateletsActa Pol. Pharm.66(3)235-242(2009) 5.Zhou, X., Wu, X., Sun, H., et al.Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysisJ. Evid. Based Med.10(2)136-144(2017)